In this issue:
Archival vs. new tumour samples for assessing PD-L1 expression and OS
HBV reactivation in B-cell lymphoma treated with obinutuzumab or rituximab
Novel microenvironment-based immune molecular subgroups in HNSCC
Inflammatory biomarkers for advanced-stage cancer treated with immunotherapy
sCTLA-4: a biomarker in metastatic melanoma treated with ipilimumab
CAR T-cell therapy landscape in the US vs. China
Soluble immune mediators and tumour responses in anti-PD-1-treated NSCLC
Pembrolizumab for melanoma with active brain metastases
Fatal toxicities with immune checkpoint inhibitors
Immune checkpoint blockade + tumour-specific vaccine for incurable HPV-16-related cancer
Please login below to download this issue (PDF)